Supernus Pharmaceuticals Announces Proposed Merger with Indivior

What Happened

• Supernus Pharmaceuticals, Inc. (SUPN) announced on August 3, 2026 that it and Indivior Pharmaceuticals Inc. are presenting details of a proposed merger of equals by webcast and conference call at 8:30 a.m. ET; Supernus will display an investor presentation (Exhibit 99.1) during the call. Indivior intends to file a registration statement on Form S-4 with the SEC that will include a joint proxy statement/prospectus for both companies.

Key Details

• Date/time: August 3, 2026 webcast and call at 8:30 a.m. Eastern Time; slides filed as Exhibit 99.1.
• Regulatory filings: Indivior to file Form S-4 containing the joint proxy statement/prospectus; definitive materials will be mailed to both companies’ stockholders when available.
• Transaction mechanics/risk notes: filing describes a fixed exchange ratio (not adjusted for market-price changes) and discloses potential effects such as additional indebtedness to fund a Special Dividend, integration costs, required stockholder and regulatory approvals, and other customary merger risks.
• Information access: Investors may obtain free copies of the S-4/joint proxy statement/prospectus and other SEC filings at www.sec.gov and on the companies’ investor websites.

Why It Matters

• This filing signals a material corporate transaction that will affect ownership, governance and the combined company’s capital structure. Retail investors should review the upcoming joint proxy statement/prospectus when filed (and before voting or making investment decisions), because it will contain detailed terms, the exchange ratio, risk factors, financing details (including any debt to fund a Special Dividend), and the approvals required to complete the merger. The 8-K is informational and not an offer or solicitation.